BR112015002384A2 - combinações farmacêuticas compreendendo um inibidor de b-raf, um inibidor de egfr e opcionalmente um inibidor de pi3k-alfa - Google Patents

combinações farmacêuticas compreendendo um inibidor de b-raf, um inibidor de egfr e opcionalmente um inibidor de pi3k-alfa

Info

Publication number
BR112015002384A2
BR112015002384A2 BR112015002384A BR112015002384A BR112015002384A2 BR 112015002384 A2 BR112015002384 A2 BR 112015002384A2 BR 112015002384 A BR112015002384 A BR 112015002384A BR 112015002384 A BR112015002384 A BR 112015002384A BR 112015002384 A2 BR112015002384 A2 BR 112015002384A2
Authority
BR
Brazil
Prior art keywords
inhibitor
pi3k
optionally
raf
egfr
Prior art date
Application number
BR112015002384A
Other languages
English (en)
Other versions
BR112015002384A8 (pt
BR112015002384B1 (pt
Inventor
Stuart Darrin
Caponigro Giordano
Moutouh-De Parseval Laure
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48980368&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015002384(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112015002384A2 publication Critical patent/BR112015002384A2/pt
Publication of BR112015002384A8 publication Critical patent/BR112015002384A8/pt
Publication of BR112015002384B1 publication Critical patent/BR112015002384B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

resumo patente de invenção: “combinações farmacêuticas compreendendo um inibidor de b-raf, um inibidor de egfr e opcionalmente um inibidor de pi3k-alfa”. a presente invenção refere-se a uma combinação farmacêutica compreendendo (a) um inibidor de b-raf, (b) um inibidor de egfr e, opcionalmente, (c) um inibidor de pi3k; usos de tal combinação no tratamento de doenças proliferativas; e métodos de tratar um sujeito sofrendo de uma doença proliferativa compreendem administrar uma quantidade terapeuticamente efetiva de tal combinação.
BR112015002384-3A 2012-08-07 2013-08-05 Combinações farmacêuticas compreendendo um inibidor de b-raf e um inibidor de egfr, e seus usos BR112015002384B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261680473P 2012-08-07 2012-08-07
US61/680,473 2012-08-07
PCT/US2013/053619 WO2014025688A1 (en) 2012-08-07 2013-08-05 Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor

Publications (3)

Publication Number Publication Date
BR112015002384A2 true BR112015002384A2 (pt) 2017-07-04
BR112015002384A8 BR112015002384A8 (pt) 2019-07-30
BR112015002384B1 BR112015002384B1 (pt) 2023-08-15

Family

ID=

Also Published As

Publication number Publication date
AR092045A1 (es) 2015-03-18
HRP20190537T1 (hr) 2019-06-28
HK1204976A1 (en) 2015-12-11
AU2013299841B8 (en) 2017-01-05
HUE042877T2 (hu) 2019-07-29
LT2882440T (lt) 2019-04-25
BR112015002384A8 (pt) 2019-07-30
JP6974669B2 (ja) 2021-12-01
UA115786C2 (uk) 2017-12-26
EA201590332A1 (ru) 2015-06-30
NZ703940A (en) 2018-04-27
EA028420B1 (ru) 2017-11-30
PE20191655A1 (es) 2019-11-07
ES2717911T3 (es) 2019-06-26
ECSP15008695A (es) 2019-03-29
SG11201500321YA (en) 2015-04-29
TR201904980T4 (tr) 2019-05-21
EP2882440A1 (en) 2015-06-17
TWI607754B (zh) 2017-12-11
TW201410247A (zh) 2014-03-16
US20150265616A1 (en) 2015-09-24
CA2879548A1 (en) 2014-02-13
CN104519887A (zh) 2015-04-15
AU2013299841B2 (en) 2016-11-24
JP2018109022A (ja) 2018-07-12
PH12015500246B1 (en) 2015-03-30
WO2014025688A1 (en) 2014-02-13
KR102112885B1 (ko) 2020-05-19
JOP20130236B1 (ar) 2021-08-17
EP3574904A1 (en) 2019-12-04
SI2882440T1 (sl) 2019-05-31
CA2879548C (en) 2020-07-21
MX2015001732A (es) 2015-06-03
CL2015000294A1 (es) 2015-05-08
HK1211831A1 (en) 2016-06-03
CY1122143T1 (el) 2020-11-25
AU2013299841A1 (en) 2015-02-12
RS58734B1 (sr) 2019-06-28
PE20150673A1 (es) 2015-05-20
KR20150040905A (ko) 2015-04-15
DK2882440T3 (da) 2019-05-06
JP6342396B2 (ja) 2018-06-13
AU2013299841A8 (en) 2017-01-05
MX359403B (es) 2018-09-26
PT2882440T (pt) 2019-04-23
IL236934B (en) 2018-11-29
CN104519887B (zh) 2017-06-27
JP6595024B2 (ja) 2019-10-23
EP2882440B1 (en) 2019-02-27
US9474754B2 (en) 2016-10-25
MA37829A1 (fr) 2017-01-31
JP2020019780A (ja) 2020-02-06
TN2015000027A1 (en) 2016-06-29
JP2015524472A (ja) 2015-08-24
GT201500025A (es) 2017-09-28
IN2015DN00450A (pt) 2015-06-26
PH12015500246A1 (en) 2015-03-30
CO7200273A2 (es) 2015-02-27
MY176031A (en) 2020-07-22
PL2882440T3 (pl) 2019-07-31

Similar Documents

Publication Publication Date Title
IN2015DN00450A (pt)
MX2015001122A (es) Combinaciones farmaceuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf.
BR112015010477A2 (pt) combinação farmacêutica que compreende um inibidor b-raf e um inibidor de histona desacetilase e o uso dos mesmos no tratamento de doenças proliferativas
MX2022013172A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
RU2018145985A (ru) Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений
MX2020010535A (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
EA201590855A1 (ru) Соединения пирролопиримидина как ингибиторы киназ
EA201291336A1 (ru) Замещенные 5-фтор-1н-пиразолопиридины и их применение
UA114476C2 (uk) Хіназолінові похідні для лікування вірусних інфекцій та подальших захворювань
EA201590655A8 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
MX2021005317A (es) Composiciones y métodos para absorción transmucosa.
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
EA201490254A1 (ru) Комбинированное лечение гепатита с
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
MX2019001977A (es) Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados.
EA201391702A1 (ru) Интраназальные тестостероновые составы с пониженной дозировкой в виде геля и их применение для лечения аноргазмии или гипоактивного расстройства сексуального желания
EA201490516A1 (ru) Бифенилкарбоксиамиды в качестве ингибиторов rock-киназ
BR112015007095A8 (pt) derivados de di-hidro-6-azafenaleno para o tratamento de doenças do snc, oncológicas e distúrbios relacionados, composição farmacêutica compreendendoos e uso dos referidos derivados
EA201491836A1 (ru) Способы лечения рака с использованием ингибитора pi3k и ингибитора mek
WO2013068993A3 (en) Tyrosine isomers as therapeutic agents
NZ745950A (en) Methods and compositions for treating multiple sclerosis and related disorders
EA201200407A1 (ru) Новые терапевтические концепции лечения фибромиалгии
TR201200212A2 (tr) Risedronat içeren geliştirilmiş formülasyonlar.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B25A Requested transfer of rights approved

Owner name: ARRAY BIOPHARMA INC. (US)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/08/2013, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.